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To the Editor,
   Schistosomiasis also named as snail fever is a combined 
name of parasitic diseases caused by several species of 
tropical trematodes belonging to the genus Schistosoma. 
Snails serve as the intermediary agent between mammalian 
hosts carrying this demonic disease. Individuals in 
developing countries who lack proper cleanliness and 
sanitation facilities and proper drinking water often fall as 
victims to contaminated water containing parasites[1].
   Skin is the initial organ of contact where the parasite 
makes its first hideout and then transforms into another 
stage (schistosomula). Lungs and liver are the next area of 
migration, where it matures into the adult form. The adult 
worm then moves to specific body part depending on its 
species and sub-species. These areas include the bladder, 
rectum, intestines, liver, portal venous system (the veins that 
carry blood from the intestines to liver), spleen, and lungs. 
Schistosomiasis is not usually seen in countries like United 
States. It is often found in many tropical and subtropical 
areas worldwide[2]. Figure 1 illustrates the developed adult 
parasite and its body parts.
Figure 1.  Schistosoma parasite.
1. Why is it named lethal?
   Schistosomiasis is the second most socioeconomically 
devastating parasitic disease after malaria. The disease 
affects many people in developing countries, particularly 
children who may acquire the disease by swimming 
or playing in infected water[3]. When children come 
into contact with a contaminated water source, the 
parasitic larvae easily enter through their skin and 
mature further within organ tissues. As of 2009, about 74 
developing countries statistically identified epidemics of 
schistosomiasis within their respective populations[4].
   The newly transformed schistosomulum may stay in 
the skin for two days before locating a post-capillary 
venule which would be the primary target; from here the 
schistosomulum travels to the lungs where it undergoes 
further developmental changes necessary for subsequent 
migration to the liver. Eight to ten days after penetration 
of the skin, the parasite migrates to the liver sinusoids. 
Schistosoma japonicum (S. japonicum) moves more quickly 
than Schistosoma mansoni (S. mansoni), and usually 
reaches the liver within eight days of penetration. Juvenile 
S. mansoni and S. japonicum parasites develop an oral 
sucker after arriving at the liver, and it is during this 
period that the parasite begins to feed on red blood cells 
thereby showing off the major symptoms in the human 
body. The nearly-mature worms pair, with the longer 
female worm residing in the gynaecophoric channel of the 
shorter male. An average adult worm measures about 10 
mm. Worm pairs of S. mansoni and S. japonicum relocate to 
the mesenteric or rectal veins. Schistosoma haematobium 
(S. haematobium) schistosomula ultimately migrate from 
the liver to the perivesical venous plexus of the bladder, 
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ureters, and kidneys through the hemorrhoidal plexus.
   Figure 2 elucidates the life cycle of the deadly tropical 
parasite. The initial step would be from water to snails where 
the parasites penetrate into the snails. The sporocysts in 
snail undergo possible changes and then are released into 
the water. After the initial part of the life cycle, the cercariae 
are released and absorbed into the skin of humans where the 
most crucial step of the life cycle occurs. The parasite does 
all the devastating effects on human body[5]. The eggs thus 
released in the body are released through stools leading to 
transmission of the disease.
   Maturity is attained by the parasites in about six to 
eight weeks, at which they begin to produce eggs. Adult 
S. mansoni pairs residing in the mesenteric vessels may 
produce up to 300 eggs per day during their reproductive 
lives. S. japonicum may produce up to 3 000 eggs per day. 
Many of the eggs pass through the walls of the blood vessels, 
and through the intestinal wall, to be passed out of the body 
in feces. S. haematobium eggs pass through the urethral or 
bladder wall and into the urine. In the digestive tract, only 
mature eggs cross the digestive tract, possibly through the 
release of proteolytic enzymes, but also as a function of host 
immune response, which fosters local tissue ulceration. 
Nearly half of the eggs released by the worm pairs become 
trapped in the mesenteric veins, or will be washed back into 
the liver. An average of four and half years is the time period 
of the worms to reside, but may even persist up to twenty 
years[6].
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Figure 2. Life cycle of the schistosomulum.
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S. japonicum
   Trapped eggs mature normally, secreting antigens that 
elicit a vigorous immune response. The eggs themselves do 
not damage the body. Rather it is the cellular infiltration 
resultant from the immune response that causes the 
pathology classically associated with schistosomiasis[7].
2. Intricacy of the parasite
   Fever, chills, lymph node enlargement, and liver 
and spleen enlargement are the general symptoms or 
complications observed by heavy infestation. Secondary 
complications also do develop from these symptoms. Initial 
invasion of the parasites into the skin may cause itching 
and a rash (swimmer’s itch). The schistosome is destroyed 
within the skin in such conditions. Intestinal symptoms 
include abdominal pain and diarrhea (which may be bloody). 
Symptoms related to the urinary system may include 
frequent urination, painful urination (dysuria), and blood in 
the urine (hematuria).
Figure 3. Patient with schistosomiasis having enlargement of the liver.
   If left untreated, the adult parasite may progress to attack 
liver and spleen, causing more complications. It can also 
infect urinary tract, increasing the risk of getting squamous 
cell carcinoma. It would trigger renal stones by causing 
secondary infection. In extreme cases, schistosomes may 
cause renal failure. If it attacks gastrointestinal tract, 
you may have complications like bleeding in the gastro-
intestine and malabsorption. There may be symptoms of iron 
deficiency and lesions begin to develop in the colon and 
also on the rectum. It can attack liver, causing fibrosis.
   On rare occasions, it can invade lungs, causing pulmonary 
hypertension or chronic pulmonary infection.
   Schistosomiasis affects the uterine environment during 
pregnancy. These pregnant women develop severe anemia, 
have low birth-weight infants, and are at increased risk for 
infant and maternal mortality. Schistosomiasis has been 
found in placenta, and newborns have been diagnosed with 
this condition, thus confirming congenital infection. Infected 
pregnant women have a higher rate of spontaneous abortions 
and a higher risk for ectopic pregnancies. In addition, 
increased pelvic blood flow during pregnancy is thought to 
increase the infection load[8]. 
3. Novel approach
   Patients should receive antischistosomal drugs and 
corticosteroids, especially if acutely ill. Steroids reduce 
inflammation and help suppress changes that result from 
killing of the parasites. As maturing schistosomes are less 
susceptible to therapy than adult worms, a second course of 
treatment is necessary. This is given several weeks after the 
first course of therapy. 
4. Praziquantel as the apt boulevard
   The drug of choice for treating all species of schistosomes 
is praziquantel. Cure rates of 65%-90% have been described 
after a single treatment with praziquatel. In individuals 
not cured, the drug causes egg excretion to be reduced by 
90%[9]. Praziquatel affects the membrane permeability of 
the parasite, which causes vacuolation of the tegument. 
It paralyses the worm and exposes it to attack by the host 
immune system. However, as praziquantel is ineffective on 
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developing schistosomula, it may not abort early infection. 
Praziquantel can be used in pregnant and lactating 
women[10]. 
   Treatment of schistosomiasis affecting the central nervous 
system consists of praziquantel with glucocorticoids. In 
central nervous system disease, corticosteroids are used to 
reduce inflammation and edema around eggs. In patients 
with neurological complications like seizures, anticonvulsant 
therapy may also be needed. Patients are to be observed 
with suspected or known cysticercosis as they may deveop 
seizures or neurologic effects from dying cysticerci. 
   World Health Organization recommends giving 
praziquantel to pregnant and lactating women to decrease 
the disease burden and improve the pregnancy and fetal 
outcomes[11].
   It was proven positive in many aspects. A retrospective 
study of 88 women with schistosomiasis who received 
praziquantel during pregnancy, in a mass treatment 
campaign, did not show an increase in the rate of abortion, 
preterm deliveries, or congenital abnormalities compared 
with untreated women[12].
5. Other antipathys
   There are no vaccines for the disease; however clinical 
studies show that artemether may be used as a prophylactic 
agent if given once every 2-4 weeks[13]. In general, travelers 
are said to be attacked most by such parasites. Topical 
lipid formulations of N, N-diethyl-m-toluamide (DEET), 
such as lipo DEET, are effective in killing schistosome 
cercariae. Minimal absorption, low cost, and a range 
of activity against insects and schistosomes make this 
compound an excellent prophylactic agent against human 
and animal schistosomiasis, especially for travelers[14]. Also 
artemether, which is used as antimalarial treatment, is also 
active against all 3 major schistosome parasites (mainly 
schistosomula)[13]. In addition, the combination of artemether 
and praziquantel can kill schistosomula during the first 3 
weeks of infection and is synergistic with praziquantel in 
killing adult worms[15]. The high efficacy of mefloquine-
artesunate against S. haematobium warrants further 
investigation. Individuals co-infected with Plasmodium and 
Schistosoma who are treated with a mefloquine-artesunate 
combination against malaria may experience a dual 
benefit: clearance of malaria parasitemia and reduction of 
schistosomiasis-related morbidity[16].
6. Conclusion
   Many such tropical parasites are existing in the world 
especially in underdeveloped and developing countries in the 
Asia-Pacific region. The weather conditions, environment, 
poverty and lack of proper sanitation are the major causes 
of rampant spread of such life taking diseases. Many of the 
parasites are life taking while some leave the individuals 
with some serious complications. Awareness, granting the 
researchers and supporting them will definitely help in 
eradicating such demons from the world. This article definitely 
acts as an active endorsement for researchers in fighting 
against schistosomiasis and saving the tropical region.
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